Pulmonary fibrosis (PF) is a chronic, progressive lung disease marked by scarring and thickening of lung tissue, impairing oxygen exchange and leading to symptoms such as breathlessness, fatigue, and reduced exercise tolerance.

Among the most prevalent forms, idiopathic pulmonary fibrosis (IPF) carries significant morbidity and mortality, with median survival rates of just 3–5 years post-diagnosis.
Despite advancements in understanding its pathophysiology—spanning genetic predispositions, environmental factors, and cellular injury—diagnosis remains complex, often delayed by nonspecific early symptoms.

iNGENū’s team of researchers and clinicians is dedicated to advancing pulmonary fibrosis research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by neuropathic pain.